Neuren Pharmaceuticals (ASX:NEU) has updated investors on the first quarter 2025 financial results announcement and conference call of its partner Acadia Pharmaceuticals.
Acadia announced first-quarter net sales of DAYBUE (trofinetide) in the US of US$84.6 million, up 11 per cent from the prior corresponding period, and reaffirmed its full-year 2025 US net sales guidance of US$380 to US$405 million.
The number of unique patients receiving a DAYBUE shipment reached a record high of 954 in the first quarter, an increase of 4 per cent from the final quarter of 2024. The company said discontinuations were down 35 per cent compared to the final three months of 2024 and down 66 per cent compared with the prior corresponding period. The persistency rate remains steady above 50 per cent at 12 months, and 65 per cent of active patients have now been on therapy for 12 months or longer.
Neuren said Acadia confirmed that first quarter 2025 DAYBUE net sales were lower than the final three months of 2024 due mainly to the typical seasonal pattern of refills brought forward from January to December and a small reduction in average net price per bottle as a result of US Medicare Part D redesign.
It said Acadia expects DAYBUE unique patients, volumes and net sales in the US to increase through 2025. "There is substantial potential for future growth in the US with two-thirds of the 5,500 to 5,800 diagnosed Rett patients yet to try DAYBUE," it said, adding, "Acadia is anticipating approval of the marketing application for Europe in Q1 2026 and continues to build EU leadership and launch teams."
Neuren said it anticipates royalties of A$13.5 million for the first quarter of 2025, up 17 per cent on the prior corresponding period and between A$62 million and A$67 million in the US for the full year 2025.